Sanofi-Aventis Asks for Delay in Start of Taxotere Trial

Aug 20, 2019
  • Sanofi-Aventis LLC, the pharmaceutical company behind chemotherapy drug Taxotere has asked a federal judge to delay the start of a trial brought by plaintiffs who claim using the drug caused them to have permanent hair loss.

    Needing More Time

    According to an article from, the legal counsel for Sanofi-Aventis LLC argued that other pending pre-trial motions have not been heard yet. They also argued that a ruling by the Supreme Court in a separate case involving Merck Pharmaceuticals, that states “judges, rather than lay juries, are better equipped to evaluate the nature and scope of an agency’s determination.”

    Motion Denied

    At the end of the day, however, it was a win for the plaintiffs. The federal judge denied the motion for at least one of the plaintiffs, and attorneys for the plaintiffs expressed their frustration at the request considering the judge had already granted the respondents a delay back in May.

    It remains to be seen how the judge will rule regarding the other individuals. Legal counsel for the plaintiffs has also argued that a delay for the trial is unfair to the other plaintiffs in the lawsuit, as many of them are ill and/or have passed away and are not being allowed a fair shake in the proceedings.

    Injured by Taxotere?

    If you or a loved one has suffered permanent hair loss as a result of using Taxotere or had any other adverse medical reaction due to the use of a pharmaceutical drug contact our team at  to schedule a free consultation. Click here to view our practice area page on pharmaceuticals for more information.